Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Sci Transl Med. 2012 Feb 15;4(121):121ra20. doi: 10.1126/scitranslmed.3002566.

Phosphorylated α-synuclein in Parkinson's disease.

Author information

  • 1Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA.

Abstract

Phosphorylated α-synuclein (PS-129), a protein implicated in the pathogenesis of Parkinson's disease (PD), was identified by mass spectrometry in human cerebrospinal fluid (CSF). A highly sensitive and specific assay was established and used to measure PS-129 together with total α-synuclein in the CSF of patients with PD, other parkinsonian disorders such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), and healthy individuals (a total of ~600 samples). PS-129 CSF concentrations correlated weakly with PD severity and, when combined with total α-synuclein concentrations in CSF, contributed to distinguishing PD from MSA and PSP. Further rigorous validation in independent cohorts of patients, especially those where samples have been collected longitudinally, will determine whether the concentration of PS-129 in CSF will be useful for diagnosing PD and for monitoring PD severity and progression.

PMID:
22344688
[PubMed - indexed for MEDLINE]
PMCID:
PMC3302662
Free PMC Article

Images from this publication.See all images (4)Free text

Fig 1
Fig 2
Fig 3
Fig 4
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk